FERNANDO
PÉREZ RUIZ
David Geffen School of Medicine at UCLA
Los Ángeles, Estados UnidosPublicaciones en colaboración con investigadores/as de David Geffen School of Medicine at UCLA (9)
2023
-
The 2023 ACR/EULAR Classification Criteria for Calcium Pyrophosphate Deposition Disease
Arthritis and Rheumatology, Vol. 75, Núm. 10, pp. 1703-1713
-
The 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease
Annals of the Rheumatic Diseases, Vol. 82, Núm. 10, pp. 1248-1257
2022
-
Identifying Potential Classification Criteria for Calcium Pyrophosphate Deposition Disease: Item Generation and Item Reduction
Arthritis Care and Research, Vol. 74, Núm. 10, pp. 1649-1658
2019
-
Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout
Annals of the Rheumatic Diseases, Vol. 78, Núm. 11, pp. 1592-1600
2017
-
Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970-2016: A systematic analysis for the Global Burden of Disease Study 2016
The Lancet, Vol. 390, Núm. 10100, pp. 1084-1150
-
Healthcare access and quality index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990-2015: A novel analysis from the global burden of disease study 2015
The Lancet, Vol. 390, Núm. 10091, pp. 231-266
-
Treat-To-Target (T2T) recommendations for gout
Annals of the Rheumatic Diseases, Vol. 76, Núm. 4, pp. 632-638
2011
-
Long-term therapy for chronic gout results in clinically important improvements in the health-related quality of life: Short form-36 is responsive to change in chronic gout
Rheumatology, Vol. 50, Núm. 4, pp. 740-745
2007
-
Outcome evaluations in gout
Journal of Rheumatology